Occupation or Discipline – Page 15

Novo Nordisk Partners with NanoVation in $600M Deal for Advanced Genetic Medicine Delivery

1 year ago talkbio0Tagged cardiometabolic diseases, Genetic Medicine, Hereditary Diseases, Lipid Nanoparticles, NanoVation, Nordisk, Technology

Novo Nordisk, NanoVation Therapeutics, Genetic Medicine, Lipid Nanoparticle (LNP) Technology, Cardiometabolic Diseases, Rare Genetic Disorders

Novo Nordisk and NanoVation Collaborate on $600M Genetic Medicine Deal for Rare and Cardiometabolic Diseases

1 year ago talkbio0Tagged base-editing therapies, cardiometabolic diseases, Genetic Medicine, lipid nanoparticle technology, NanoVation, Nordisk, Obstetric Delivery, RNA

Novo Nordisk, NanoVation, genetic medicine, lipid nanoparticle technology, cardiometabolic diseases, rare diseases, RNA delivery, base-editing therapies

Revolutionizing Drug Discovery: AI-Driven Solutions for Efficient and Personalized Treatments

1 year ago talkbio0Tagged Artificial Intelligence, Computation (action), Drug Development, Drug Discovery, Efficient, Identification (Psychology), Machine Learning, Machine Learning, Pharmaceutical Research, Precision Medicine, processes, QML, quantum, Quantum Machine Learning, Target, Validation

Artificial Intelligence (AI) in Drug Discovery, Machine Learning (ML) for Drug Development, Quantum Computing in Pharmaceutical Research, Personalized Medicine, Efficient Drug Discovery Processes, AI-Driven Target Identification and Validation, Quantum Machine Learning (QML) for Drug Discovery

Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options

1 year ago talkbio0Tagged Approved, Enhanze Drug Delivery, Halozyme, Hybreza, Immunotherapy for cancer, Inhibitor, PD-L1, Roche (company), subcutaneous administration, Tecentriq, Technology, United States Food and Drug Administration

Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology